200 related articles for article (PubMed ID: 22231987)
1. Targeted delivery of proteins into the central nervous system mediated by rabies virus glycoprotein-derived peptide.
Fu A; Wang Y; Zhan L; Zhou R
Pharm Res; 2012 Jun; 29(6):1562-9. PubMed ID: 22231987
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of large fusion protein into hippocampal neurons by systemic administration.
Xiang L; Zhou R; Fu A; Xu X; Huang Y; Hu C
J Drug Target; 2011 Sep; 19(8):632-6. PubMed ID: 20932231
[TBL] [Abstract][Full Text] [Related]
3. Targeted transport of nanocarriers into brain for theranosis with rabies virus glycoprotein-derived peptide.
Fu C; Xiang Y; Li X; Fu A
Mater Sci Eng C Mater Biol Appl; 2018 Jun; 87():155-166. PubMed ID: 29549945
[TBL] [Abstract][Full Text] [Related]
4. The kinetics and tissue distribution of protein transduction in mice.
Cai SR; Xu G; Becker-Hapak M; Ma M; Dowdy SF; McLeod HL
Eur J Pharm Sci; 2006 Mar; 27(4):311-9. PubMed ID: 16376528
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system.
Zhang Y; Pardridge WM
Stroke; 2001 Jun; 32(6):1378-84. PubMed ID: 11387502
[TBL] [Abstract][Full Text] [Related]
6. A novel peptide delivers plasmids across blood-brain barrier into neuronal cells as a single-component transfer vector.
Fu A; Zhang M; Gao F; Xu X; Chen Z
PLoS One; 2013; 8(3):e59642. PubMed ID: 23555734
[TBL] [Abstract][Full Text] [Related]
7. The potential use of rabies virus glycoprotein-derived peptides to facilitate drug delivery into the central nervous system: a mini review.
Huey R; Hawthorne S; McCarron P
J Drug Target; 2017 Jun; 25(5):379-385. PubMed ID: 27581650
[TBL] [Abstract][Full Text] [Related]
8. Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease.
Park TE; Singh B; Li H; Lee JY; Kang SK; Choi YJ; Cho CS
Biomaterials; 2015 Jan; 38():61-71. PubMed ID: 25457984
[TBL] [Abstract][Full Text] [Related]
9. [Zebrafish as a model animal for the study of blood-brain barrier permeability by biomolecules].
Fu AL; Chen HY; Xu XR; Zhao BQ
Yao Xue Xue Bao; 2012 Nov; 47(11):1447-51. PubMed ID: 23387075
[TBL] [Abstract][Full Text] [Related]
10. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice.
Kilic U; Kilic E; Dietz GP; Bähr M
Stroke; 2003 May; 34(5):1304-10. PubMed ID: 12677018
[TBL] [Abstract][Full Text] [Related]
11. Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury.
Khalin I; Alyautdin R; Wong TW; Gnanou J; Kocherga G; Kreuter J
Drug Deliv; 2016 Nov; 23(9):3520-3528. PubMed ID: 27278330
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection in experimental stroke with targeted neurotrophins.
Wu D
NeuroRx; 2005 Jan; 2(1):120-8. PubMed ID: 15717063
[TBL] [Abstract][Full Text] [Related]
13. Design, stability and efficacy of a new targeting peptide for nanoparticulate drug delivery to SH-SY5Y neuroblastoma cells.
Huey R; Rathbone D; McCarron P; Hawthorne S
J Drug Target; 2019 Nov; 27(9):959-970. PubMed ID: 30623678
[TBL] [Abstract][Full Text] [Related]
14. RVG29-modified docetaxel-loaded nanoparticles for brain-targeted glioma therapy.
Hua H; Zhang X; Mu H; Meng Q; Jiang Y; Wang Y; Lu X; Wang A; Liu S; Zhang Y; Wan Z; Sun K
Int J Pharm; 2018 May; 543(1-2):179-189. PubMed ID: 29555442
[TBL] [Abstract][Full Text] [Related]
15. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier.
Kim JY; Choi WI; Kim YH; Tae G
Biomaterials; 2013 Jan; 34(4):1170-8. PubMed ID: 23122677
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of β-amyloid and ibotenic acid into the bilateral hippocampus.
Feng C; Zhang C; Shao X; Liu Q; Qian Y; Feng L; Chen J; Zha Y; Zhang Q; Jiang X
Int J Pharm; 2012 Feb; 423(2):226-34. PubMed ID: 22193058
[TBL] [Abstract][Full Text] [Related]
17. Targeted drug delivery system to neural cells utilizes the nicotinic acetylcholine receptor.
Huey R; O'Hagan B; McCarron P; Hawthorne S
Int J Pharm; 2017 Jun; 525(1):12-20. PubMed ID: 28412449
[TBL] [Abstract][Full Text] [Related]
18. Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice.
Kilic E; Dietz GP; Hermann DM; Bähr M
Ann Neurol; 2002 Nov; 52(5):617-22. PubMed ID: 12402259
[TBL] [Abstract][Full Text] [Related]
19. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion.
Zhang Y; Pardridge WM
Brain Res; 2006 Sep; 1111(1):227-9. PubMed ID: 16884698
[TBL] [Abstract][Full Text] [Related]
20. Enhanced transport of plant-produced rabies single-chain antibody-RVG peptide fusion protein across an in cellulo blood-brain barrier device.
Phoolcharoen W; Prehaud C; van Dolleweerd CJ; Both L; da Costa A; Lafon M; Ma JK
Plant Biotechnol J; 2017 Oct; 15(10):1331-1339. PubMed ID: 28273388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
